{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Section', 'Change', 'Rationale', 'SYNOPSIS', '-', '\"If necessary, patients may receive', 'Wording adjusted to', 'rescue therapy, which will be limited to', 'enhance clarification.', 'RESCUE THERAPY', 'Plasma Exchange (PLEX),', '\"', '4.1. Summary of Trial Design', 'changed to', '\"Rescue therapy will be limited to', 'RESCUE THERAPY', 'Plasma Exchange (PLEX),', '\"', '\"In situations where rescue therapy is', 'given, patients will be discontinued', 'early from randomized treatment.\"', 'changed to', '\"In situations where the treatments as', 'listed above are given under the', 'protocol defined rescue criteria,', 'patients will be discontinued early from', \"randomized treatment.'\", 'SYNOPSIS', 'Criterion no. 5:', 'Administrative change', 'Inclusion Criteria', '\"Note: AChE inhibitors must be held for at', 'least \"', '4.3.1 Inclusion Criteria', 'changed to', '\"Note: AChE inhibitors must be halted for', 'at least', '\"', 'SYNOPSIS', 'Criterion no. 7:', 'Typo/wrong use of \"i.e.\"', '\"Patients with known autoimmune disease', 'was corrected, additional', 'Exclusion Criteria', 'other than MG (i.e., autoimmune', 'example provided.', '4.3.2 Exclusion Criteria', 'thyroiditis) that', '\"', 'changed to', '\"Patients with known autoimmune disease', 'other than MG (for example autoimmune', 'thyroiditis, rheumatoid arthritis,', ') that', 'SYNOPSIS', '\"ethnicity\" was replaced twice with', 'Administrative changes', 'Statistical Methods and Plan', '\"Japanese/non-Japanese patient, AChR-', '(added for completeness).', 'Ab\".', '8.4.1. Primary Endpoint', 'Analyses', 'argenx BVBA', 'Confidential', 'Page 11 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Section', 'Change', 'Rationale', 'Table 1 General Schedule of', 'Trial Day (Visit Window).', 'Visit window corrected.', 'Assessments', 'Changes to the table footer:', 'Administrative changes.', '-', '\"k Samples for clinical laboratory tests', '(hematology and clinical chemistry)\"', 'changed to', '\"k Samples for clinical laboratory tests', '(hematology, clinical chemistry and', 'FSH, if applicable)\"', '\"q Samples for anti-drug antibodies', '(ADAs) will be collected pre-dose on', 'dosing days. As from of the', 'corresponding Treatment Cycle.\"', 'changed to', '\"q Samples for anti-drug antibodies', '(ADAs) will be collected pre-dose if', 'sampling is to be performed on dosing', 'days. During the first Treatment Cycle,', 'samples for ADA will be taken at', 'Visits 1, 4, 6 and 9. As from', 'of the', 'corresponding Treatment Cycle and', 'EoS/ED.\"', '\" Pharmacokinetic (PK) samples will', 'be collected at Visits 1, 2, 3, 4, 5, and', '6.\"', 'changed to', '\" Pharmacokinetic (PK) samples will', 'be collected at Visits 1, 2, 3, 4, 5, and 6', 'and EoS/ED.\"', '\" During the UNS visit, additional', 'assessments can be performed at', '\"', 'changed to', '\" During the UNS visit, additional', 'assessments as indicated in the SoA', 'can be performed at', '\"', 'LIST OF APPENDICES', 'Appendix 8 and Appendix 9 were added', 'For completeness.', 'LIST OF ABBREVIATIONS', 'Cmax', 'Correction', '\"Maximum observed plasma', 'concentration\"', 'changed to', '\"Maximum observed serum concentration\"', 'argenx BVBA', 'Confidential', 'Page 12 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Section', 'Change', 'Rationale', '4.6. Protocol Deviations', '\"prior review and documented approval', 'Administrative change', 'from the Institutional Review', 'Board/Independent Ethics Committee', '(IRB/IEC) of an amendment, except', '\"', 'changed to', '\"prior review and documented approval of', 'an amendment from the Institutional', 'Review Board/Independent Ethics', 'Committee (IRB/IEC) and Regulatory', 'Authority as per local regulation, except', '\"', '4.9. End of Trial Definition', 'The following was added:', 'Added for completeness', '\"4.9. End of Trial Definition', '(was missing in the previous', 'version).', 'End of trial is defined as last patient last', 'visit.\"', '5.2. Screening', '12th bullet:', 'To avoid missing', 'information on stratification', '\"Sampling to determine the AChR/MuSK-', 'factor (at time of', 'Ab serotype (seronegative or seropositive)', 'randomization) in case of', 'of the patient.\"', 'late lab results', 'changed to', '\"Sampling to determine the AChR/MuSK-', 'Ab serotype (seronegative or seropositive)', 'of the patient. In case the AChR-Ab result', 'is not available in time (within the 2 weeks', 'screening window), the value found in the', 'Medical History of the patient will be used', 'for randomization. \"', '5.3. Randomization', 'Last paragraph:', '\"Japanese\" is a race and not', '\"', 'an ethnicity.', '3 stratification factors: ethnicity', '(Japanese vs. non-Japanese), AChR-Ab', 'status \"', 'changed to', '\" 3 stratification factors: Japanese vs.', 'non-Japanese patients, AChR-Ab status', '\"', '\"', 'recorded as a screen failure in the', 'Correction.', 'IRT.\"', 'changed to', '\"', 'recorded as a screen failure in the', 'EDC system.\"', 'argenx BVBA', 'Confidential', 'Page 13 of 110']\n\n###\n\n", "completion": "END"}